Rajiv Shukla was appointed as Executive Chairman at Longevity Health Holdings, Inc..
“Name Age Position(s) Rajiv Shukla 48 Executive Chairman”
Longevity Health Holdings, Inc. — fact timeline
Source-grounded facts extracted from Longevity Health Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Rajiv Shukla was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class III directors: Randy Hubbell, Patrick Sturgeon and Rajiv Shukla.”
Patrick Sturgeon was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class III directors: Randy Hubbell, Patrick Sturgeon and Rajiv Shukla.”
Randy Hubbell was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class III directors: Randy Hubbell, Patrick Sturgeon and Rajiv Shukla.”
Jaime Garza was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class II directors: Steve Bariahtaris, Kathryn Gregory and Jaime Garza.”
Kathryn Gregory was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class II directors: Steve Bariahtaris, Kathryn Gregory and Jaime Garza.”
Steve Bariahtaris was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class II directors: Steve Bariahtaris, Kathryn Gregory and Jaime Garza.”
David Anderson was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class I directors: Rich Upton, William Newlin and David Anderson.”
William Newlin was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class I directors: Rich Upton, William Newlin and David Anderson.”
Rich Upton was appointed as Director at Longevity Health Holdings, Inc..
“• Three Class I directors: Rich Upton, William Newlin and David Anderson.”
Longevity Health Holdings, Inc. shareholders approved Advisory Charter Proposal E - To provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66 2/3% of the Combined Company’s then-outstanding shares of capital stock entitled to vote on such amendment. at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Advisory Charter Proposal E, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 9,938,520 5,572,559 0”
Longevity Health Holdings, Inc. shareholders approved Advisory Charter Proposal D - To provide that the removal of any director be only for cause and by the affirmative vote of at least 66 2/3% of the Combined Company’s then-outstanding shares of capital stock entitled to vote generally in the election of directors. at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Advisory Charter Proposal D, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 9,938,520 5,572,559 0”
Longevity Health Holdings, Inc. shareholders approved Advisory Charter Proposal C - To increase the authorized shares of 'blank check' preferred stock that the Combined Company’s board of directors could issue to 20,000,000 shares. at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Advisory Charter Proposal C, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 10,030,205 5,480,874 0”
Longevity Health Holdings, Inc. shareholders approved Advisory Charter Proposal B - To increase the authorized shares of ALPA Common Stock to 250,000,000 shares. at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Advisory Charter Proposal B, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 12,006,101 3,504,978 0”
Longevity Health Holdings, Inc. shareholders approved Advisory Charter Proposal A - To change the corporate name of the Combined Company to 'Carmell Therapeutics Corporation' at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Advisory Charter Proposal A, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 12,006,101 3,504,978 0”
Longevity Health Holdings, Inc. shareholders approved To adopt a proposal to approve, assuming the Business Combination Proposal is approved and adopted, a proposed third amended and restated certificate of incorporation, which will amend and restate ALPA’s current Amended and Restated Certificate of Incorporation. at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Charter Amendment Proposal, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 7,576,108 (Class A Common Stock) 3,590,151 (Class A Common Stock) 0 (Class A Common Stock) 3,861,026 (Class B Common Stock) 0 (Class B Common Stock) 0 (Class B Common Stock)”
Longevity Health Holdings, Inc. shareholders approved To adopt a proposal to (a) adopt and approve the Business Combination Agreement, dated as of January 4, 2023, among ALPA, Candy Merger Sub, Inc., and Carmell Therapeutics Corporation, and (b) approve such merger and the other transactions contemplated by the Business Combination Agreement. at the 2023-07-11 meeting.
“The following is a tabulation of the votes with respect to the Business Combination Proposal, which was approved by the Company’s stockholders: Votes For Votes Against Abstentions 12,006,101 3,504,978 0”
Longevity Health Holdings, Inc. entered into Non-Redemption Agreement with Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, and Meteora Select Trading Opportunities Master, LP (collectively, "Seller") (effective 2023-07-09).
“Also on July 9, 2023, in connection with the foregoing, the Seller entered into a Non-Redemption Agreement with Alpha pursuant to which the Seller agreed not to exercise redemption rights under the Charter with respect to an aggregate of 100,000 Shares.”
Longevity Health Holdings, Inc. entered into Forward Purchase Agreement with Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, and Meteora Select Trading Opportunities Master, LP (collectively, "Seller") (effective 2023-07-09).
“On July 9, 2023, Alpha and each of Meteora Special Opportunity Fund I, LP (“ MSOF ”), Meteora Capital Partners, LP (“ MCP ”) and Meteora Select Trading Opportunities Master, LP (“ MSTO ”) (with MCP, MSOF, and MSTO collectively as “ Seller ”) entered into a forward purchase agreement (the “ Forward Purchase Agreement ” ) for an OTC Equity Prepaid Forward Transaction.”
Longevity Health Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).
“March 29, 2023, Alpha Healthcare Acquisition Corp. III (the “ Company ”) received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company was not in compliance with Listing Rule 5550(a)(3), which requires the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market (the “ Minimum Public Holders Rule ”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Na”
Longevity Health Holdings, Inc. entered into Business Combination Agreement with Carmell Therapeutics Corporation valued at an implied Carmell equity value of $150,000,000 (effective 2023-01-04).
“On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (the " Company "), entered into a business combination agreement (the " Business Combination Agreement ") by and among the Company, Candy Merger Sub, Inc., a Delaware corporation (" Merger Sub "), and Carmell Therapeutics Corporation, a Delaware corporation (" Carmell ").”
William Woodward was appointed as Director at Longevity Health Holdings, Inc..
“On July 26, 2021, in connection with the IPO, Darlene T. DeRemer, Eugene L. Podsiadlo and William Woodward (the “New Directors” and, collectively with Rajiv Shukla, the “Directors”) were appointed to the board of directors of the Company (the “Board”).”
Eugene L. Podsiadlo was appointed as Director at Longevity Health Holdings, Inc..
“On July 26, 2021, in connection with the IPO, Darlene T. DeRemer, Eugene L. Podsiadlo and William Woodward (the “New Directors” and, collectively with Rajiv Shukla, the “Directors”) were appointed to the board of directors of the Company (the “Board”).”
Darlene T. DeRemer was appointed as Director at Longevity Health Holdings, Inc..
“On July 26, 2021, in connection with the IPO, Darlene T. DeRemer, Eugene L. Podsiadlo and William Woodward (the “New Directors” and, collectively with Rajiv Shukla, the “Directors”) were appointed to the board of directors of the Company (the “Board”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.